Number of the records: 1

Mebendazole prodrugs with enhanced solubility and oral bioavailability

SYSNO ASEP	0580041
Document Type	P - Patent
R&D Document Type	Patent or other outcome protected by special legislation
Title	Mebendazole prodrugs with enhanced solubility and oral bioavailability
Author(s)	Slusher, B. (US) Rais, R. (US) Riggins, G. (US) Majer, Pavel (UOCHB-X) Tichý, Tomáš (UOCHB-X)_RID Vávra, Jan (UOCHB-X)_RID Jančařík, Andrej (UOCHB-X)_{ORCID, RID} Tenora, Lukáš (UOCHB-X)_ORCID
Year of issue	2023
Possible third party use of the result	A - Pro využití výsledku jiným subjektem je vždy nutné nabytí licence
Royalty requested	A - Poskytovatel licence požaduje licenční poplatek
Patent no. or utility model no. or industrial design no.	AU2019216757
Date of the patent acceptance	14.09.2023
Name of the patent owner	The Johns Hopkins University - Ústav organické chemie a biochemie AV ČR, v. v. i
Code of the issuer name	AU001 - IP Australia Phillip ACT
Current use	B - Patent je využíván na základě uzavřené licenční smlouvy mezi vlastníkem a uživatelem
Territorial Protection	NEU - národní patent v zemi mimo EU PCT - mezinárodní patentová ochrana dle Smlouvy o patentové spolupráci
Language	eng - English
Keywords	mebendazole ; prodrug ; oral bioavailability
OECD category	Medicinal chemistry
Institutional support	UOCHB-X - RVO:61388963
Annotation	Prodrugs of mebendazole and methods for their use in treating a disease, disorder, or disorder, including cancer, are disclosed.
Workplace	Institute of Organic Chemistry and Biochemistry
Contact	asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Jana Procházková, Tel.: 220 183 418
Year of Publishing	2024
Electronic address	https://worldwide.espacenet.com/patent/search/family/067549070/publication/AU2019216757B2?q=AU2019216757B2

Number of the records: 1